NRX Pharmaceuticals, Inc.

NRXP

NRX Pharmaceuticals, Inc.

NRXP

Insider Sentiment (TTM):

Last Purchase:2024-12-17Last Sale:2022-12-07Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:6,129,883Shares Outstanding:32,325,323Institutional Ownership Pct.:18.96%

Earnings Market Reaction:

Filing Date:2026-08-14Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Series Convertible Preferred Stock	-	-	-	-	-	-	-	-	-	12	3	12
Assets
Assets Current
Assets Current	29	7	9	12	5	7	3	4	5	3	7	13
Cash And Cash Equivalents At Carrying Value	27	7	8	7	3	6	1	2	2	1	5	9
Accounts Receivable Net Current	0	0	0	0	-	-	0	-	-	-	-	-
Prepaid Expense And Other Assets Current	2	0	1	1	2	2	2	2	3	2	2	4
Equity Method Investments	0	0	0	-	-	-	0	-	-	-	-	-
Property Plant And Equipment Net	1	0	0	0	-	-	0	-	-	-	-	-
Operating Lease Right Of Use Asset	-	-	-	0	-	-	-	-	-	-	-	-
Intangible Assets Net Excluding Goodwill	1	1	1	2	-	-	0	-	-	-	-	-
Goodwill	2	2	2	1	-	-	0	-	-	-	-	-
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	34	12	13	15	5	8	4	4	5	4	7	13
Liabilities And Stockhold…
Accounts Payable Current	3	4	4	4	4	4	4	5	5	6	5	4
Accrued Liabilities Current	-	-	-	-	-	-	-	-	-	5	5	5
Liabilities Current
Liabilities Current	34	25	29	41	40	33	22	20	-	-	19	19
Convertible Notes Payable	-	-	-	-	-	-	-	-	8	-	-	-
Convertible Notes Payable Current	-	-	0	10	10	8	1	3	-	-	9	-
Loans Payable Current	-	-	0	0	0	0	0	1	1	-	0	-
Derivative Liabilities	-	-	-	-	-	-	-	-	0	-	-	-
Derivative Liabilities Current	19	9	12	16	16	10	6	2	-	0	0	0
Accumulated Other Comprehensive Income Loss Net Of…	-	-	-	-	-	-	0	0	-0	-0	-0	-0
Convertible Long Term Notes Payable	-	-	0	0	0	0	5	3	-	-	0	-
Liabilities	34	26	29	41	40	33	27	23	24	19	19	19
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Stockholders Equity
Stockholders Equity	-0	-14	-16	-26	-36	-25	-23	-19	-18	-15	-12	-6
Additional Paid In Capital	325	294	291	281	266	259	255	250	249	245	241	243
Retained Earnings Accumulated Deficit	-325	-308	-307	-307	-301	-284	-278	-269	-268	-260	-253	-249
Liabilities And Stockholders Equity	34	12	13	15	5	8	4	4	5	4	7	13
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	50	50	50	50	50	50	50	50	50	50	50	50
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	500	500	500	500	500	500	500	500	500	500	500	500
Common Stock Shares Issued	43	33	32	28	19	17	15	11	11	96	8	8
Shares Outstanding	43	33	32	28	19	17	15	11	11	96	8	8

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	26.22%	17.99%	-3.96%	-	-	-	-	-	-	-	-	-
2025	36.25%	40.83%	7.92%	1.45%	14.86%	-11.23%	-5.22%	5.22%	-15.66%	44.07%	85.31%	116.95%
2024	0.94%	-21.70%	-33.33%	-12.37%	-17.20%	-25.54%	5.17%	131.90%	160.34%	-23.83%	-12.60%	12.34%
2023	-	-	-	-	-	-	-5.14%	18.86%	8.29%	-	-	-
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	0.86	0.29	0.31	0.29	0.11	0.22	0.15	0.20	-	-	0.36	0.68
Quick Ratio	0.79	0.27	0.28	0.26	0.07	0.17	0.07	0.08	-	-	0.24	0.46
Working Capital	-4.72M	-17.82M	-19.69M	-28.65M	-35.86M	-25.50M	-18.56M	-16.19M	-	-	-12.16M	-6.24M
Leverage & Debt
Debt to Equity	-201.94	-1.86	-1.81	-1.58	-1.14	-1.30	-1.16	-1.24	-	-	-1.62	-3.11
Interest Coverage TTM	-17.39	-18.94	-24.18	-	-	-	-80.44	-66.05	-66.46	-69.71	-231.98	-833.00
Debt Ratio	1.00	2.16	2.23	2.72	8.36	4.32	7.36	5.22	-	-	2.60	1.47
Efficiency & Turnover
Asset Turnover TTM	0.17	0.24	0.15	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding TTM	22.15	28.81	47.97	360.48	-	-	-	-	-	-	-	-
Receivables Turnover TTM	16.48	12.67	7.61	1.01	-	-	-	-	-	-	-	-
Per Share Metrics
Diluted EPS TTM	-	-	-	-	-	-	-	-	-	-2.90	-	-4.40
Free Cash Flow Per Share TTM	-0.58	-0.55	-0.79	-0.52	-0.47	-0.64	-1.00	-1.07	-1.33	-2.17	-2.86	-3.27
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	46.64%	-	-	-	-	-	-	-	-	-	-	-
Operating Profit Margin TTM	-586.15%	-746.58%	-1,324.41%	-5,798.76%	-	-	-	-	-	-	-	-
Net Profit Margin TTM	-691.78%	-1,070.21%	-2,336.49%	-15,727.69%	-	-	-	-	-	-	-	-
Growth Metrics
Net Income Growth (1Y)	-30.52%	1.78%	13.91%	86.67%	36.11%	-6.00%	-16.69%	-43.46%	-36.47%	-31.32%	-24.14%	-88.58%
EPS Growth (1Y)	-66.90%	-48.33%	-43.34%	-7.85%	-20.18%	-49.29%	-40.70%	-57.78%	-55.77%	-48.43%	-34.14%	-90.74%
Valuation Metrics
P/E TTM	-6.56	-2.81	-2.03	-1.93	-1.73	-1.40	-0.93	-0.91	-1.03	-1.63	-1.16	-0.59
P/B TTM	-905.80	-4.98	-3.64	-2.85	-1.64	-1.34	-1.01	-0.99	-1.40	-2.77	-2.97	-3.43
P/S TTM	45.37	30.03	47.35	303.15	-	-	-	-	-	-	-	-
Market Cap	153.99M	68.85M	58.00M	73.36M	58.47M	33.64M	23.42M	18.55M	25.66M	41.78M	34.85M	21.31M
Enterprise Value	127.30M	62.14M	50.20M	76.24M	65.79M	36.49M	28.55M	23.57M	24.71M	40.46M	39.42M	12.40M
Calculated Values
Free Cash Flow TTM	-21.70M	-17.67M	-16.86M	-11.58M	-8.43M	-10.45M	-10.64M	-11.73M	-13.99M	-19.24M	-21.67M	-26.79M
Net Debt	-26.69M	-6.71M	-7.80M	2.88M	7.32M	2.85M	5.13M	5.02M	-955.00K	-1.32M	4.57M	-8.90M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2024-12-17Purchase

Owner: Javitt, Jonathan C

Title: Chairman and Chief Scientist

Shares: 40,000

Price/Share: $1.17

Value: $46,800.00

Shares Owned: 84,634

Relationship: Director,Officer,TenPercentOwner

Ownership: Direct

2023-08-30Purchase

Owner: Hurvitz, Chaim

Title: -

Shares: 70,000

Price/Share: $0.29

Value: $20,300.00

Shares Owned: 570,000

Relationship: Director

Ownership: Direct

2023-08-30Purchase

Owner: Gorovitz, Aaron

Title: -

Shares: 35,000

Price/Share: $0.32

Value: $11,200.00

Shares Owned: 105,000

Relationship: Director

Ownership: Indirect

2023-08-23Purchase

Owner: Javitt, Jonathan C

Title: Chief Scientist

Shares: 100,000

Price/Share: $0.33

Value: $33,000.00

Shares Owned: 446,332

Relationship: Director,Officer,TenPercentOwner

Ownership: Direct

2023-08-22Purchase

Owner: Javitt, Jonathan C

Title: Chief Scientist

Shares: 200,000

Price/Share: $0.32

Value: $64,000.00

Shares Owned: 346,332

Relationship: Director,Officer,TenPercentOwner

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2024-12-17	Javitt, Jonathan C	Director,Officer,TenPercentOwner	Chairman and Chief Scientist	Direct	Purchase	40,000	1.17	$46,800.00	84,634	4
2023-08-30	Hurvitz, Chaim	Director	-	Direct	Purchase	70,000	0.29	$20,300.00	570,000	4
2023-08-30	Gorovitz, Aaron	Director	-	Indirect	Purchase	35,000	0.32	$11,200.00	105,000	4
2023-08-23	Javitt, Jonathan C	Director,Officer,TenPercentOwner	Chief Scientist	Direct	Purchase	100,000	0.33	$33,000.00	446,332	4
2023-08-22	Javitt, Jonathan C	Director,Officer,TenPercentOwner	Chief Scientist	Direct	Purchase	200,000	0.32	$64,000.00	346,332	4
2022-12-16	Van, Voorhees Seth	Officer	CHIEF FINANCIAL OFFICER	Direct	Purchase	30,000	1.10	$33,000.00	46,337	4
2022-12-16	Willard, Stephen H	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Purchase	50,000	1.17	$58,500.00	50,000	4
2022-12-07	Javitt, Jonathan C	Director,TenPercentOwner	-	Indirect	Sale	400,000	1.00	$400,000.00	12,899,997	4
2022-11-30	Javitt, Daniel C.	TenPercentOwner	-	Indirect	Sale	8,441	1.50	$12,661.50	9,634,793	4
2022-11-28	Flynn, Patrick John	Director	-	Direct	Purchase	1,750	1.25	$2,187.50	1,750	4
2022-11-25	Van, Voorhees Seth	Officer	CHIEF FINANCIAL OFFICER	Direct	Purchase	16,337	1.11	$18,134.07	16,337	4/A
2022-11-18	Hurvitz, Chaim	Director	-	Direct	Purchase	40,408	1.10	$44,448.80	500,000	4/A
2022-11-17	Javitt, Daniel C.	TenPercentOwner	-	Indirect	Sale	33,018	1.05	$34,668.90	9,656,964	4
2022-11-11	Javitt, Daniel C.	TenPercentOwner	-	Indirect	Sale	49,200	1.01	$49,692.00	9,823,701	4
2022-07-29	Javitt, Daniel C.	TenPercentOwner	-	Indirect	Sale	784,063	1.01	$791,903.63	9,872,901	4
2022-06-07	Javitt, Daniel C.	TenPercentOwner	-	Indirect	Sale	86,459	0.65	$56,198.35	12,656,964	4
2022-06-01	Javitt, Jonathan C	Director,Officer,TenPercentOwner	Chief Scientist	Direct	Purchase	100,000	0.58	$58,000.00	146,332	4/A
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

18.96%

Inst. Shares: 6,129,883

Shares Outstanding: 32,325,323

2025-12-31

24.46%

Inst. Shares: 5,235,517

Shares Outstanding: 21,401,683

2025-09-30

17.80%

Inst. Shares: 3,956,630

Shares Outstanding: 22,231,178

2025-06-30

16.69%

Inst. Shares: 2,993,679

Shares Outstanding: 17,934,196

2025-03-31

13.77%

Inst. Shares: 2,259,891

Shares Outstanding: 16,410,062

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	6,129,883	32,325,323	18.96%
2025-12-31	5,235,517	21,401,683	24.46%
2025-09-30	3,956,630	22,231,178	17.80%
2025-06-30	2,993,679	17,934,196	16.69%
2025-03-31	2,259,891	16,410,062	13.77%
2024-12-31	1,047,453	10,644,461	9.84%
2024-09-30	714,327	10,973,697	6.51%
2024-06-30	493,320	10,517,460	4.69%
2024-03-31	3,541,226	8,852,286	40.00%
2023-12-31	3,743,031	7,576,176	49.41%
2023-09-30	3,545,829	8,194,696	43.27%
2023-06-30	9,856,415	7,322,156	134.61%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

NRX Pharmaceuticals, Inc. (NRXP) — SEC Financial Statements & Analysis

NRX Pharmaceuticals, Inc. (NRXP) is a pharmaceutical preparations company, incorporated in DE. NRX Pharmaceuticals, Inc. trades on Nasdaq as: NRXP. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), NRX Pharmaceuticals, Inc. reported a Gross Profit Margin of 46.64% (TTM), a Debt-to-Equity ratio of -201.94x, a Price-to-Sales (P/S) ratio of 45.37x (TTM), a Price-to-Book (P/B) ratio of -905.80x (TTM), at a market cap of $153.99M. Figures below are sourced from SEC EDGAR, as-filed.

Gross Profit Margin TTM: 46.64%
Debt To Equity: -201.94x
P/S TTM: 45.37x
P/B TTM: -905.80x
Market Cap: $153.99M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is NRX Pharmaceuticals, Inc. in?

NRX Pharmaceuticals, Inc. (NRXP) operates in the Pharmaceutical Preparations industry.

What is NRXP's market cap?

NRX Pharmaceuticals, Inc. (NRXP) has a market capitalization of $153.99M as of 2026-06-30.

What exchange does NRXP trade on?

NRX Pharmaceuticals, Inc. (NRXP) trades on the Nasdaq.

Where is NRX Pharmaceuticals, Inc. incorporated?

NRX Pharmaceuticals, Inc. is incorporated in DE.